Edwards Lifesciences
S&P 500
$84.37
-2.77%
Delayed · cached 15 min
Fair value analysis
EW
Edwards Lifesciences
$84.37
Close used for this calculation
$33.24Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
48/100
Quality radar
Consensus fair value
$33.24
Above FV▼ -60.6% against the close used
Model range $11.51 – $42.65
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$11.51Fair value$33.24Bull$42.65
FairClose
52-week traded range
52W low $72.6552W high $95.18
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Edwards Lifesciences closed at $84.37, 153.8% above the consensus fair value of $33.24 drawn from 8 valuation models.
Financial DNA score 48/100 — Average. P/E of 46.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$42.65
-49.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
$27.51
-67.4%
√(22.5 × EPS × BVPS)
EPS=1.83, BVPS=18.38 · outside Graham range (P/E 46.1, P/B 4.6) — asset-light, treat as a rough floor
P/E Fair Value
$36.60
-56.6%
EPS × 20x (sector P/E)
EPS=1.83, Sector P/E=20x
Peter Lynch (PEG)
$11.51
-86.4%
EPS × Growth% (PEG = 1 is fair)
EPS=1.83, g=6.3%
EV/EBITDA
$24.22
-71.3%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=1.42B
Book Value (P/B)
$18.67
-77.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=18.38, ROE=10.1%, g=3%, r=10%
Reverse DCF
$84.37
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 18.4% | Historical: -6.3%
Margin of Safety
$26.69
-68.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=35.59, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.